Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies

Targeted kinase inhibitors and camptothecins have shown preclinical and clinical activity in several cancers. This trial evaluated the maximum tolerated dose (MTD) and dose‐limiting toxicities of sorafenib and topotecan administered orally in pediatric patients with relapsed solid tumors. Sorafenib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Reed, Damon R., Mascarenhas, Leo, Manning, Kathleen, Hale, Gregory A., Goldberg, John, Gill, Jonathan, Sandler, Eric, Isakoff, Michael S., Smith, Tiffany, Caracciolo, Jamie, Lush, Richard M., Juan, Tzu‐Hua, Lee, Jae K., Neuger, Anthony M., Sullivan, Daniel M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735769/
https://ncbi.nlm.nih.gov/pubmed/26714427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.598
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados